铁死亡在肿瘤治疗作用中的研究进展

doi:10.16352/j.issn.1001-6325.2022.11.1781

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (11): 1781-1784.doi: 10.16352/j.issn.1001-6325.2022.11.1781

铁死亡在肿瘤治疗作用中的研究进展

王冯宇, 李亘, 林晓伊, 姚欣悦, 陈毓^*

杭州医学院, 浙江杭州 310051

收稿日期:2021-07-16 修回日期:2021-12-08 出版日期:2022-11-05 发布日期:2022-11-01
通讯作者: ^* cheny1124@163.com
基金资助:
浙江省自然科学基金探索项目(LQ20H280002);浙江省教育厅科研项目(Y201942763);国家级大学生创新创业训练计划(202013023016)

Research progress on the role of ferroptosis in the treatment of tumors

WANG Feng-yu, LI Gen, LIN Xiao-yi, YAO Xin-yue, CHEN Yu^*

Hangzhou Medical College,Hangzhou 310051,China

Received:2021-07-16 Revised:2021-12-08 Online:2022-11-05 Published:2022-11-01
Contact: ^* cheny1124@163.com

摘要/Abstract

摘要： 铁死亡作为一种受调控的、非凋亡的细胞死亡形式,为肿瘤治疗提供了新的研究方向。铁死亡参与某些肿瘤耐药性的产生,也参与许多肿瘤疗法的治疗过程,是一种在肿瘤治疗中被忽视的机制。本文将从肿瘤化学治疗、肿瘤放射治疗和肿瘤免疫治疗等方面,介绍铁死亡与不同的肿瘤疗法之间的联系,归纳总结铁死亡提高肿瘤治疗效果的策略,以期为肿瘤治疗提供借鉴。

关键词: 铁死亡, 细胞死亡, 肿瘤

Abstract: Ferroptosis, as a regulated and non-apoptotic form of cell death, provides a new research direction for tumor therapy. Ferroptosis is involved in the development of drug resistance in some tumors and also in the treatment process of many tumor therapies, which is a neglected mechanism in tumor therapy. This article will introduce the relationship between ferroptosis and different tumor treatment therapies from the aspects of tumor chemotherapy, tumor radiation therapy and tumor immunotherapy, and summarize the strategies of improving tumor treatment effect by ferroptosis, in order to provide reference for tumor treatment.

Key words: ferroptosis, cell death, tumor

中图分类号:

王冯宇, 李亘, 林晓伊, 姚欣悦, 陈毓. 铁死亡在肿瘤治疗作用中的研究进展[J]. 基础医学与临床, 2022, 42(11): 1781-1784.

WANG Feng-yu, LI Gen, LIN Xiao-yi, YAO Xin-yue, CHEN Yu. Research progress on the role of ferroptosis in the treatment of tumors[J]. Basic & Clinical Medicine, 2022, 42(11): 1781-1784.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.11.1781

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I11/1781

参考文献 21

[1]	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149: 1060-1072.
[2]	Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156:317-331.
[3]	姜学东,李文雅.Erastin诱导人非小细胞肺癌细胞系A549凋亡[J].基础医学与临床,2021,41:1313-1317.
[4]	Song Z, Xiang X, Li J, et al. Ruscogenin induces ferroptosis in pancreatic cancer cells[J]. Oncol Rep, 2020, 43:516-524.
[5]	Guan Z, Chen J, Li X, et al. Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation[J]. Biosci Rep, 2020, 40: BSR20201807. doi:10.1042/BSR20201807.
[6]	Yuan B, Liao F, Shi ZZ, et al. Dihydroartemisinin inhibits the proliferation, colony formation and induces ferroptosis of lung cancer cells by inhibiting PRIM2/SLC7A11 Axis[J]. Onco Targets Ther, 2020, 13: 10829-10840.
[7]	Liu G, Kuang S, Cao R, et al. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway[J]. FASEB J, 2019, 33: 10089-10103.
[8]	Li Y, Yan H, Xu X, et al. Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway[J]. Oncol Lett, 2020, 19: 323-333.
[9]	Sehm T, Fan Z, Ghoochani A, et al. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema[J]. Oncotarget, 2016, 7: 36021-36033.
[10]	Li M, Chen X, Wang X, et al. RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction[J]. Biochem Pharmacol, 2021, 192: 114741. doi:10.1016/j.bcp.2021.114741.
[11]	Jiang Z, Lim SO, Yan M, et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis[J]. J Clin Invest, 2021, 131:e139434. doi:10.1172/JCI139434.
[12]	Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature, 2019, 569: 270-274.
[13]	Jiang Q, Wang K, Zhang X, et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy[J]. Small, 2020, 16: e2001704. doi:10.1002/smll.202001704.
[14]	Ping Z, Peng Y, Lang H, et al. Oxidative stress in radiation-induced cardiotoxicity[J]. Oxid Med Cell Longev, 2020, 2020: 1-15.
[15]	Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11[J]. Cancer Discov, 2019, 9: 1673-1685.
[16]	Ye LF, Chaudhary KR, Zandkarimi F, et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers[J]. ACS Chem Biol, 2020, 15: 469-484.
[17]	Li X, Zhuang X, Qiao T. Role of ferroptosis in the process of acute radiation-induced lung injury in mice[J]. Biochem Biophys Res Commun, 2019,519: 240-245.
[18]	Shibata Y, Yasui H, Higashikawa K, et al. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo[J]. PLoS One, 2019;14:e0225931. doi:10.1371/journal.pone.0225931.
[19]	Zhang Y, Tan H, Daniels JD, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model[J]. Cell Chem Biol, 2019, 26: 623-633.
[20]	Klein S, Wegmann M, Distel LVR, et al. APTES-Terminated ultrasmall and iron-doped silicon nanoparticles as X-Ray dose enhancer for radiation therapy[J]. Biophys Res Commun, 2018, 498: 855-861.
[21]	Wan X, Song L, Pan W, et al. Tumor-targeted cascade nanoreactor based on metal-organic frameworks for synergistic ferroptosis-starvation anticancer therapy[J].ACS Nano, 2020, 14: 11017-11028.

铁死亡在肿瘤治疗作用中的研究进展

Research progress on the role of ferroptosis in the treatment of tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙慧, 陈思宇. 微生物相关肿瘤的发病机制及其治疗的研究进展[J]. 基础医学与临床, 2023, 43(1): 178-182.
[2]	庄志诚, 官国先. 铁死亡在结直肠癌治疗中的作用[J]. 基础医学与临床, 2023, 43(1): 174-177.
[3]	王世尊, 张丹, 葛明, 冯海凉, 刘玉琴. 可移植人髓母细胞瘤PUMC-MBT1瘤株的建立与鉴定[J]. 基础医学与临床, 2022, 42(9): 1339-1343.
[4]	李贺同, 任晶晶, 王文豪, 郝敏. 雌激素及其受体协同HPV在宫颈癌肿瘤微环境中作用的研究进展[J]. 基础医学与临床, 2022, 42(9): 1438-1442.
[5]	周美岑, 兰玲, 邓微. RNA结合蛋白在甲状腺癌发病机制中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1306-1309.
[6]	薛晋芳, 宋海飞, 陈国兵. 程序性细胞死亡在脓毒症发生发展中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1284-1287.
[7]	徐娟, 李晔. 铁死亡在阿尔茨海默病中作用的研究进展[J]. 基础医学与临床, 2022, 42(7): 1129-1133.
[8]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[9]	周岚, 张生贵, 胡祖梁, 王添贤, 岳鹏鹏, 于鸿浩. 基于CRISPR/Cas9系统高效编辑小鼠miR let-7a[J]. 基础医学与临床, 2022, 42(6): 857-863.
[10]	马瑞, 杨黎星, 陈秋霞, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐对小鼠胶质瘤相关巨噬细胞系促癌表型的影响[J]. 基础医学与临床, 2022, 42(5): 701-707.
[11]	李钊璇, 罗云萍, 陈翀. 气液交互法培养小鼠来源的肿瘤类器官的建立及优化[J]. 基础医学与临床, 2022, 42(5): 782-787.
[12]	白小腾, 孙晓红, 赵翔宇, 李子坚. 检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展[J]. 基础医学与临床, 2022, 42(4): 661-666.
[13]	宋昊昕, 叶菜英, 朱蕾. Blau综合征细胞模型的建立[J]. 基础医学与临床, 2022, 42(3): 406-410.
[14]	刘畅, 郭向阳. 局部麻醉药物在肿瘤转移和复发中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 512-515.
[15]	谢丽君, 朱高红, 赵继华, 张海波, 王娇. 甲状腺癌肿瘤干细胞的来源和存活途径[J]. 基础医学与临床, 2022, 42(2): 321-324.